Enveric Releases Paper Detailing The Development Of Novel Psilocin Prodrugs For The Treatment Of Mental Health Disorders

Enveric Biosciences, Inc. ENVB has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A manuscript describing the research has been submitted for peer-reviewed publication and is currently accessible via the following open access platform: https://biorxiv.org/cgi/content/short/2023.05.16.540994v1.

The paper entitled, “Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders,” outlines comprehensive research performed by scientists at Enveric, supported by affiliated partners at the University of Calgary, and led by Dr. Peter Facchini, Ph.D., professor of biochemistry and chief innovation officer at Enveric.

Foundational to the work was the creation of a library of novel prodrug derivatives of psilocin, the active metabolite responsible for the effects of psilocybin, incorporating a diversity of established and metabolically favorable functional groups that reduce the duration of the psychedelic experience produced by psilocybin, while maintaining the long-term mental health benefits. Beginning with twenty-eight unique compounds representing nine distinct prodrug classes, the researchers screened each molecule to generate five unique prodrug derivatives with properties matching and exceeding psilocybin. Of these active prodrugs, two distinct molecules were selected to proceed further as potential therapies for anxiety disorders.

“The research described in this manuscript demonstrates the potential of Enveric’s discovery platform and engine to identify and develop novel psilocin prodrugs that offer key improvements over conventional psilocybin-assisted therapies,” stated Joseph Tucker, Ph.D., director and CEO of Enveric Biosciences. “Our lead product candidate, EB-373, which was derived from this important work, offers the potential to elicit a more rapid onset of action, more controlled therapeutic effect, and reduced side-effects, which we believe differentiates it from other drugs as a potential novel treatment for anxiety disorders.”

Price Action

Enveric Biosciences shares were trading 18.93% lower at $2.87 per share at the time of writing Monday morning.

Photo: Benzinga edit with photos by 4339272 on pixabay and Nathalie De Boever on pexels

Related News

Enveric Bio Stock Spikes 115% After Its Novel Prodrug Of Psilocin Receives Notice Of Allowance From US Patent And Trademark Office